Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. From Wikipedia
The deal, expected to close in mid-2024, comes as AbbVie's top-selling drug Humira faces competition from lower-priced generics.
